Discovery of an Anion-Dependent Farnesyltransferase Inhibitor from a Phenotypic Screen

  • ACS Med Chem Lett. 2020 Dec 23;12(1):99-106. doi: 10.1021/acsmedchemlett.0c00551.
Marina Bukhtiyarova  1 ,  Erica M Cook  1 ,  Paula J Hancock  1 ,  Alan W Hruza  2 ,  Anthony W Shaw  1 ,  Gregory C Adam  1 ,  Richard J O Barnard  1 ,  Philip M McKenna  1 ,  M Katharine Holloway  1 ,  Ian M Bell  1 ,  Steve Carroll  1 ,  Ivan Cornella-Taracido  3 ,  Christopher D Cox  1 ,  Peter S Kutchukian  1 ,  David A Powell  1 ,  Corey Strickland  2 ,  B Wesley Trotter  3 ,  Matthew Tudor  1 ,  Scott Wolkenberg  1 ,  Jing Li  1 ,  David M Tellers  1
Affiliations
  • 1. MRL, Merck & Co., Inc., West Point, Pennsylvania 19486, United States.
  • 2. MRL, Merck & Co., Inc., Kenilworth, New Jersey, 07033, United States.
  • 3. MRL, Merck & Co., Inc., Boston, Massachusetts, 02115, United States.
Abstract

By employing a phenotypic screen, a set of compounds, exemplified by 1, were identified which potentiate the ability of histone deacetylase inhibitor vorinostat to reverse HIV latency. Proteome enrichment followed by quantitative mass spectrometric analysis employing a modified analogue of 1 as affinity bait identified Farnesyl Transferase (FTase) as the primary interacting protein in cell lysates. This ligand-FTase binding interaction was confirmed via X-ray crystallography and temperature dependent fluorescence studies, despite 1 lacking structural and binding similarity to known FTase inhibitors. Although multiple lines of evidence established the binding interaction, these ligands exhibited minimal inhibitory activity in a cell-free biochemical FTase inhibition assay. Subsequent modification of the biochemical assay by increasing anion concentration demonstrated FTase inhibitory activity in this novel class. We propose 1 binds together with the anion in the active site to inhibit Farnesyl Transferase. Implications for phenotypic screening deconvolution and HIV reactivation are discussed.

Products